Combination therapy with low dose ruxolitinib and cyclosporine in murine immune bone marrow failure
RNA-seq (gene expression) · mouse · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 30 samples: 6 conditions, mostly with about 6 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Efficacy of combined low-dose ruxolitinib and cyclosporine in murine immune bone marrow failureHaematologica · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE240867_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1005598 and SRA study SRP455172. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 21 samples read as cases, 3 as controls.
How we read this: 6 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7710972 CByB6F1 BMF untreated-1 CByB6F1 BMF untreated
- GSM7710973 CByB6F1 BMF untreated-2 CByB6F1 BMF untreated
- GSM7710974 CByB6F1 BMF untreated-3 CByB6F1 BMF untreated
- GSM7710975 CByB6F1 BMF CSA-treated-4 CByB6F1 BMF CSA-treated
- GSM7710976 CByB6F1 BMF CSA-treated-5 CByB6F1 BMF CSA-treated
- GSM7710977 CByB6F1 BMF CSA-treated-6 CByB6F1 BMF CSA-treated
- GSM7710978 CByB6F1 BMF RUX-treated-7 CByB6F1 BMF RUX-treated
- GSM7710979 CByB6F1 BMF RUX-treated-8 CByB6F1 BMF RUX-treated
- GSM7710980 CByB6F1 BMF RUX-treated-9 CByB6F1 BMF RUX-treated
- GSM7710981 CByB6F1 BMF RUX+CSA-treated-10 CByB6F1 BMF RUX+CSA-tre…
- GSM7710982 CByB6F1 BMF RUX+CSA-treated-11 CByB6F1 BMF RUX+CSA-tre…
- GSM7710983 CByB6F1 BMF RUX+CSA-treated-12 CByB6F1 BMF RUX+CSA-tre…
- GSM7710984 CByB6F1 BMF untreated-13 CByB6F1 BMF untreated
- GSM7710985 CByB6F1 BMF untreated-14 CByB6F1 BMF untreated
- GSM7710986 CByB6F1 BMF untreated-15 CByB6F1 BMF untreated
- GSM7710987 CByB6F1 BMF CSA-treated-16 CByB6F1 BMF CSA-treated
- GSM7710988 CByB6F1 BMF CSA-treated-17 CByB6F1 BMF CSA-treated
- GSM7710989 CByB6F1 BMF CSA-treated-18 CByB6F1 BMF CSA-treated
- GSM7710990 CByB6F1 BMF RUX-treated-19 CByB6F1 BMF RUX-treated
- GSM7710991 CByB6F1 BMF RUX-treated-20 CByB6F1 BMF RUX-treated
- GSM7710992 CByB6F1 BMF RUX-treated-21 CByB6F1 BMF RUX-treated
- GSM7710993 CByB6F1 BMF RUX+CSA-treated-22 CByB6F1 BMF RUX+CSA-tre…
- GSM7710994 CByB6F1 BMF RUX+CSA-treated-23 CByB6F1 BMF RUX+CSA-tre…
- GSM7710995 CByB6F1 BMF RUX+CSA-treated-24 CByB6F1 BMF RUX+CSA-tre…
- GSM7711027 CByB6F1 normal-1 CByB6F1 normal
- GSM7711028 CByB6F1 normal-2 CByB6F1 normal
- GSM7711029 CByB6F1 normal-3 CByB6F1 normal
- GSM7711030 CByB6F1 RUX-treated-4 CByB6F1 RUX-treated
- GSM7711031 CByB6F1 RUX-treated-5 CByB6F1 RUX-treated
- GSM7711032 CByB6F1 RUX-treated-6 CByB6F1 RUX-treated
- GSE342349 CT26 multi-tissue RNA-seq under immunotherapy combinations 72 samples shares combination, therapy
- GSE333360 Distinct neuroinflammatory effects of individual chemotherapeutics shape chemotherapy-induced peripheral neuropathy in a novel mouse model of CVAD combination regimen. 30 samples shares combination, therapy
- GSE317949 Rational design of immune gene therapy combinations via in vivo CRISPR activation screening of tumor microenvironment modulators [APCM_BulkRNASeq_OT1] 15 samples shares combination, therapy
- GSE255514 Rational design of immune gene therapy combinations via in vivo CRISPR activation screening of tumor microenvironment modulators [Bulk RNA-seq] 15 samples shares combination, therapy
- GSE284107 Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD 15 samples shares combination, ruxolitinib
- GSE337208 scRNA seq. of PDAC models treated with Kras inhibitors in combination with checkpoint immunotherapy 9 samples shares combination, therapy
- GSE249630 Modeling T cell temporal response to cancer immunotherapy rationalize development of combinatorial treatments protocols 1372 samples shares therapy
- GSE327494 Localized PD-1 CAR T therapy reprograms neuroinflammation - mouse CAR T data. 302 samples shares therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.